Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

DiaMedica Therapeutics (DMAC) EBIT: 2017-2024

Historic EBIT for DiaMedica Therapeutics (DMAC) over the last 8 years, with Dec 2024 value amounting to -$26.7 million.

  • DiaMedica Therapeutics' EBIT fell 30.85% to -$2.8 million in Q4 2019 from the same period last year, while for Dec 2019 it was -$11.6 million, marking a year-over-year decrease of 71.49%. This contributed to the annual value of -$26.7 million for FY2024, which is 25.46% down from last year.
  • Latest data reveals that DiaMedica Therapeutics reported EBIT of -$26.7 million as of FY2024, which was down 25.46% from -$21.3 million recorded in FY2023.
  • In the past 5 years, DiaMedica Therapeutics' EBIT registered a high of -$12.7 million during FY2020, and its lowest value of -$26.7 million during FY2024.
  • For the 3-year period, DiaMedica Therapeutics' EBIT averaged around -$20.6 million, with its median value being -$21.3 million (2023).
  • Data for DiaMedica Therapeutics' EBIT shows a maximum YoY tumbled of 51.90% (in 2023) over the last 5 years.
  • DiaMedica Therapeutics' EBIT (Yearly) stood at -$12.7 million in 2020, then declined by 7.46% to -$13.6 million in 2021, then dropped by 2.60% to -$14.0 million in 2022, then crashed by 51.90% to -$21.3 million in 2023, then fell by 25.46% to -$26.7 million in 2024.